Država: Malta
Jezik: engleski
Izvor: Malta Medicines Authority
DUTASTERIDE, TAMSULOSIN HYDROCHLORIDE
Uropharm AG
G04CA52
DUTASTERIDE, TAMSULOSIN HYDROCHLORIDE
HARD CAPSULE
DUTASTERIDE 0.5 milligram(s) ; TAMSULOSIN HYDROCHLORIDE 0.4 milligram(s)
POM
UROLOGICALS
Licence number in the source country: NOT APPLICAPABLE
Authorised
2020-03-26
1 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT DUTASTERIDE/TAMSULOSIN UROPHARM 0.5MG/0.4 MG HARD CAPSULES dutasteride/tamsulosin hydrochloride READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Dutasteride/Tamsulosin Uropharm is and what it is used for 2. What you need to know before you take Dutasteride/Tamsulosin Uropharm 3. How to take Dutasteride/Tamsulosin Uropharm 4. Possible side effects 5. How to store Dutasteride/Tamsulosin Uropharm 6. Contents of the pack and other information 1. WHAT DUTASTERIDE/TAMSULOSIN UROPHARM IS AND WHAT IT IS USED FOR DUTASTERIDE/TAMSULOSIN UROPHARM IS USED TO TREAT MEN WITH AN ENLARGED PROSTATE ( _benign _ _prostatic hyperplasia_ ) - a non-cancerous growth of the prostate gland, caused by producing too much of a hormone called dihydrotestosterone. Dutasteride/Tamsulosin Uropharm is a combination of two different medicines called dutasteride and tamsulosin. Dutasteride belongs to a group of medicines called _5-alpha reductase inhibitors_ and tamsulosin belongs to a group of medicines called _alpha-blockers_ . As the prostate grows, it can lead to urinary problems, such as difficulty in passing urine and a need to go to the toilet frequently. It can also cause the flow of the urine to be slower and less forceful. If left untreated, there is a risk that your urine flow will be completely blocked ( _acute urinary _ _retention_ ). This requires immediate medical treatment. Sometimes surgery is necessary to remove or reduce the size of the prostate gland. Dutasteride l Pročitajte cijeli dokument
1 1. NAME OF THE MEDICINAL PRODUCT Dutasteride/Tamsulosin Uropharm 0.5mg/0.4mg hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each hard capsule contains 0.5 mg dutasteride and 0.4 mg tamsulosin hydrochloride (equivalent to 0.367 mg tamsulosin). Excipients with known effect Each capsule contains lecithin (which may contain soya oil) and sunset yellow FCF (E 110). Each capsule contains ≤ 0.1 mg sunset yellow FCF. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Hard capsule Oblong, around 24 mm length, hard capsules with a brown body and an orange cap. Each hard capsule contains tamsulosin hydrochloride modified release pellets and one dutasteride soft gelatin capsule. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH). Reduction in the risk of acute urinary retention (AUR) and surgery in patients with moderate to severe symptoms of BPH. For information on effects of treatment and patient populations studied in clinical trials please see section 5.1. _ _ 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Adults (including elderly) _ The recommended dose of Dutasteride/Tamsulosin Uropharm is one capsule (0.5 mg/ 0.4mg) once daily. Where appropriate, Dutasteride/Tamsulosin Uropharm may be used to substitute concomitant dutasteride and tamsulosin hydrochloride in existing dual therapy to simplify treatment. Page 2 of 21 Where clinically appropriate, direct change from dutasteride or tamsulosin hydrochloride monotherapy to Dutasteride/Tamsulosin Uropharm may be considered. _Renal impairment _ The effect of renal impairment on dutasteride-tamsulosin pharmacokinetics has not been studied. No adjustment in dosage is anticipated for patients with renal impairment (see section 4.4 and 5.2). _ _ _Hepatic impairment _ The effect of hepatic impairment on dutasteride-tamsulosin pharmacokinetics has not been studied so caution should be used in patients with mild to moderate hepatic impairment (see section 4.4 an Pročitajte cijeli dokument